Innovation Stock Price, News & Analysis

IPIX OTC Link

Company Description

Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company focusing on developing innovative therapies to address various unmet medical needs such as inflammatory diseases, cancer, and infectious diseases. The company recently received patents for Host Defense Protein (HDP) Mimetics and Arylamide Compounds, strengthening its Brilacidin intellectual property rights. Brilacidin, a Host Defense Protein-mimetic drug candidate, shows promise in treating inflammatory diseases of the gastrointestinal tract, viral infections, Ulcerative Proctitis/Ulcerative Proctosigmoiditis, Crohn's Disease, and moderate-to-severe hospitalized cases of COVID-19. Innovation Pharmaceuticals is actively involved in out-licensing its products, with a recent focus on Brilacidin and its potential in fungal diseases. The company is also exploring opportunities to diversify its portfolio through evaluating other investment prospects.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

40 %

Performance 1 year

$1.0M

Market Cap

518.3M

Shares outstanding

Latest News

View All

August 28, 2023

2.67%

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024

earnings fda approval

June 21, 2023

1.57%

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases

June 5, 2023

1.66%

Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing

April 17, 2023

15.48%

Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications

March 15, 2023

12.50%

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers

February 23, 2023

7.65%

Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission

fda approval

SEC Filings

View All

No SEC filings available for Innovation.

Financial Highlights

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Loading short interest data...

Days to Cover History

Last 12 Months

Loading days to cover data...

Frequently Asked Questions

What is the current stock price of Innovation (IPIX)?

The current stock price of Innovation (IPIX) is $0.0007 as of November 7, 2025.

What is the market cap of Innovation (IPIX)?

The market cap of Innovation (IPIX) is approximately 1.0M. Learn more about what market capitalization means .

What is Innovation Pharmaceuticals focused on?

Innovation Pharmaceuticals is primarily focused on developing innovative therapies for inflammatory diseases, cancer, and infectious diseases.

What recent achievements has the company made?

The company recently obtained patents for Host Defense Protein (HDP) Mimetics and Arylamide Compounds, strengthening its Brilacidin intellectual property rights.

Which diseases is Brilacidin being tested for?

Brilacidin is being tested for various conditions including inflammatory diseases of the gastrointestinal tract, viral infections, Ulcerative Proctitis/Ulcerative Proctosigmoiditis, Crohn's Disease, and moderate-to-severe hospitalized cases of COVID-19.

What is the significance of out-licensing products for Innovation Pharmaceuticals?

Innovation Pharmaceuticals is actively out-licensing its products to partners, with a recent focus on Brilacidin and its potential in fungal diseases.

How does Innovation Pharmaceuticals plan to diversify its portfolio?

In addition to its core focus, the company is evaluating other investment opportunities to diversify its portfolio and add value.